CoChat

Idiopathic Pulmonary Fibrosis

Raghu, Ganesh, Richeldi, Luca, Jagerschmidt, Alexandre, Martin, Valerie, Subramaniam, Arun, Ozoux, Marie-Laure, Esperet, Corinne A., Soubrane, Christina · 2018 · Chest
Cited by 95

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease with 3 to 5 years' survival. Although FVC is used to assess disease progression and treatment response, identifying predictive circulating blood biomarkers could help identify specific biologic pathways for treatment. An international, prospective, noninterventional, case‐controlled, 52‐week study was therefore conducted to identify a clinical and biomarker baseline profile predictive of longitudinal disease behavior. METHODS: Patients with IPF and control subjects had lung function tests and blood sampling for biomarker quantification (control subjects at baseline only). The primary end point was disease progression rate (composite end point: decrease ≥ 10% from baseline in FVC % predicted, decrease ≥ 15% from baseline in diffusing capacity of the lung for carbon monoxide % predicted, lung transplantation, death) at week 52 and its relationship to selected biomarkers at baseline. RESULTS: Altogether, 211 subjects (154 patients with IPF and 57 control subjects) were enrolled; one‐third of patients (n = 47) with IPF had progressed by week 52. Biomarkers CC‐chemokine ligand 18 (CCL18), intercellular adhesion molecule 1, Krebs von den Lungen‐6, surfactant protein (SP)‐A, SP‐D, matrix metallopeptidase 7, urokinase‐type plasminogen activator receptor, and two novel biomarkers, human epididymis protein‐4 (HE4) and prostasin, discriminated patients with IPF vs control subjects. There was no difference in baseline CCL18 concentration between progressors and nonprogressors at week 52 (area under the receiver operating characteristic curve, 0.62; corrected P = .161). No biomarkers were predictive for disease progression. CONCLUSIONS: Several biomarkers, including CCL18, were associated with IPF, but none predicted disease progression. Two novel biomarkers, HE4 and prostasin, were identified and warrant further investigation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.chest.2018.08.1083

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 95

Metadata

Authors
Raghu, G., Richeldi, L., Jagerschmidt, A., Martin, V., Subramaniam, A., Ozoux, M.-L., Esperet, C. A., & Soubrane, C.
Venue
Chest
Publisher
Elsevier BV
Published
2018-12
Volume
154
Issue
6
Pages
1359-1370
ISSN
0012-3692 (ISSN-L)
OpenAlex
W2902697612
Cited by
95
References
7
FWCI
7.61
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Idiopathic Pulmonary Fibrosis. https://app.cochat.ai/papers/10.1016/j.chest.2018.08.1083
The paper
Raghu, G., Richeldi, L., Jagerschmidt, A., Martin, V., Subramaniam, A., Ozoux, M.-L., Esperet, C. A., & Soubrane, C. (2018). Idiopathic Pulmonary Fibrosis. Chest. https://doi.org/10.1016/j.chest.2018.08.1083

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.